Skip to main content
OpenTrials
Completed

NCT Number: NCT04642820

Drugs Brain and Behavior (DDP)

In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stimulant Use

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Chicago

Chicago, Illinois, 60637, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI between 19 and 26
  • Right Handed
  • Less than 4 alcohol or caffeinated beverages a day.

Exclusion criteria

  • High blood pressure
  • Any medical condition requiring regular medication
  • Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
  • Individuals with a history of dependence on stimulant drugs
  • Women who are pregnant or trying to become pregnant.

Treatment and study plan

Methamphetamine

Drug

Participants will be given 20 mg of Methamphetamine.

Placebo oral tablet

Drug

Participants will be given a placebo capsule that will only contain lactose.

Primary outcomes

  1. Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ).

    Time frame: Time Frame: Day 1(baseline), 3

    Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Drugs Brain and Behavior

Acronym: DDP

Important dates

Study start
2020
Primary completion
2023
Study completion
2024
First posted
Nov 24, 2020
Registry last updated
Jan 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.